EY Report: Biotech Crests In 2015, But Deal Wave Expected
The biotech sector had several prosperous years, but has seen a slowdown in recent months. Yet, analysts believe the M&A environment is poised for an upswing.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.